Infleqtion Secures Three Major DOE Projects Under Genesis Mission
Craig-Hallum initiates coverage on Infleqtion with a Buy rating and $19 price target.
Already have an account? Sign in.
Craig-Hallum initiates coverage on Infleqtion with a Buy rating and $19 price target.
Abivax shares fell after Scorpion Capital claimed its ulcerative colitis drug is toxic. The company rejected the report and reaffirmed its Phase 3 data.
CrowdStrike is reportedly in talks to acquire Zscaler in a potential $265 billion cybersecurity deal, one of the largest in the sector.
Canadian Solar shares fell sharply after a report that the solar firm and its Recurrent Energy unit are considering asset sales and a possible Chapter 11 filing.
Be the first to know when deals break, stocks move, or biotech headlines hit.